Abbott atrasentan filing delay
Abbott will not file NDA for oncologic agent atrasentan (ABT-627) until 2004, following the failure of drug to reach its primary endpoint of time-to-progression in a Phase III trial evaluating patients with advanced metastatic hormone-refractory prostate cancer. Abbott previously hoped to file in late 2003 (1"The Pink Sheet" July 2, 2001, p. 22)...
You may also be interested in...
Abbott plans to file an NDA for its prostate cancer therapy atrasentan in late 2003, the company told securities analysts at its June 21 R&D Day in New York City.
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.